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SUMMARY
Patients during radiotherapy for head and neck tumours show side effects in the oral cavity that
might influence further treatment, or even cause temporary or total break in the irradiation. For this
reason, prevention and treatment are essential to avoid or reduce the possibility of such
complications. Sanitation of the oral cavity by a dentist is indispensable, and afterwards, regular
screening of the teeth and the mucous membrane condition. Proper hygiene plays a particularly
important role, leading to alleviation of symptoms and reduction in the discomfort, which in cones-
quence, contributes to the increase in the living comfort of patients undergoing radiotherapy.
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Epidemiological data show that tumours
within the head and neck constitute 5%
of all malignant changes [1]. Atkinson's et
al. research reported in 1993 that only 50%
of the total number of his patients had
survived 5 years; this figure has not
changed for over 20 years [2]. In 1995,
in the United States 39,750 new cases
of such tumours were recorded. A similar
incidence was noted in Holland, where
about 3,500 new cases of head and neck
tumours are detected annually. Therefore,
each year 23/100.000 people are afflicted
by this disease [3].
Within the oral cavity, the leading
malignant changes are those caused
by the by cancer stemming from the lip,
tongue, mucous membrane (of the cheek
and gum), and the floor of the mouth. Other
tumours, including melanoma, occur
relatively seldom.
Among the most important causes of can-
cer, exposure to cigarette smoke and pro-
tracted alcohol consumption, play a do-
minant role [4,5,6,7,8]. Genetic factors,
however, cannot be excluded, as pointed
out by Schuster-Kolbe and Zheng and
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Jahnke [4,9,10]. Early detection and a rela-
tively prompt onset of the therapy are
crucial for the prognosis. Radiotherapy
combined with chemotherapy and surgical
removal of the changes belong to the basic
treatment methods. This method, however,
may evoke a certain number of undesirable
effects due to the fact that ionizating
radiation not only affects the changed cells,
but also the healthy ones [11,12,13]. Post-
irradiation changes within the oral cavity are
difficult to avoid. The effects of radiotherapy
and possible complications depend on
the age of the patient, conditions and
intensity of radiation, extent and time limit
of irradiation, the volume of the dose,
the density of ionization, the radiated site,
the patient's sensibility, and the distance
from the radiation source during irradiation.
During and after therapy the patients
frequently complain of taste and feeling
disorders, loss of appetite, disphagy,
dryness in the oral cavity and throat,
difficulties in swallowing, chewing,
the feeling of burning, hyper-sensibility
to temperature, self-existent pain, pain
at eating and swallowing (stomach
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and intestine effects may appear),
and sometimes lock-jaw and difficulties
in speech [14,15,16,17].
The following symptoms and sign can also
be detected clinically:
• changes in the mucous membrane
of the oral cavity (inflammatory changes,
congestion and bleeding from the mucous
membrane are the first symptoms;
erosions and ulceration may appear later),
• decrease in the secretion of saliva
(as an effect of inflammatory and dege-
nerative changes in the acidophilic
and salivary glands canals),
• intensification of caries (indirect influence
of irradiation, ionic movements within
the enamel, decrease in the secretion
of saliva, increase in the activity of pro-
teolytic enzymes, decrease in the number
of neutrocytes, increase in the bacterial
flora including flora causing caries),
• increase in the mycosic bacterial flora
connected with marrow suppression
(agranulocythophenia,
trombocythophenia), drop in the number
of neutrocytes and the IgA immuno-
globulins, decrease in the secretion
of saliva, physical and chemical factors,
and
• bone necrosis (a symptom that appears
relatively late) [11,12,15,18,19].
The complications set in during irradiation
lead to for intervals in the treatment,
and can cause its early termination.
Therefore, to limit the possibility of appea-
rance and intensification of side effects,
fractional doses are applied (at scheduled
intervals). In order to prevent or reduce
undesirable symptoms in patients under-
going radiotherapy for head and neck
cancer, close co-operation among the radio-
therapist, dentist and the patient is nece-
ssary. The patient under treatment suffers
from depression, is concentrated on his
or her treatment, on the existing distur-
bances and pain that accompany
the disease and hospitalization, effects
as a result, among others things, the oral
cavity hygiene is often disregarded
[6,20,21]. Prevention must be started before
treatment is applied. The patient shuld
be made aware of the possibility of com-
plications and their symptoms, should be
recommended a proper diet, and instructed
on prosthetic fillings. Professional pre-
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ventive measures should be started.
The dentist should pay particular attention
to caries treatment, reduction of tartar
through professional teeth cleaning,
application of anti-bacterial remedies,
and increase of the immunity of the teeth
hard tissue with fluorine preparations.
In some particularly young patients the
teeth furrows may be covered with
a sealing-wax. Proper motivation and pa-
tient training in the oral cavity hygiene are
equally important. It is also recommended
to take a panoramic X-ray picture of the up-
per and lower jaws to assess the condition
of the teeth and alvelous outgrowth, as well
as to exclude morbid centers [3,22].
Prior to treatment, the risk of recurrent
caries must be taken into account - this
problem often appears in patients
undergoing irradiation [23]. The preferred
treatment method is prevention (eg. recon-
struction of the teeth instead of denture
implantation). Movable dentures must
adhere properly, because pressure
on a changed mucous membrane may
quickly lead to sores, erosions and ulce-
ration. When the development of caries
cannot be stopped, tbe patient should
be informed about it. Local fluorine
application is essential to increase
its content in the surface enamel layers.
Billings' observation shows that in patients
with a temporary decreased saliva flow,
after the application of fluorine preparations
higher fluorine levels in the oral cavity are
sustained longer than in patients with
normal secretion. It is recommended that
caries decrements should be using
glassiomers [24]. The treated or new caries
centers should b,e at least filled with zinc
oxide and eugenol [22]. It is important
to pay attention to metal elements
in the oral cavity, particularly to metal
bridgeworks and amalgamate fillings.
During irradiation X-rays emit secondary
electrons, may increase the dose to, their
neighborhood and lead to a local damage
in the mucous membrane.
Supportive treatment of the cancer of the
head and neck consists of the follOWing
stages:
• alleviation of suffering and symptoms
connected with the cancer,
• prevention and alleviation of undesirable
treatment results (particularly the effects
Rep. Pract. Oncol. Radiother. 5 (4) 2000
Stryjski et al.: Prevention and treatment ...
of radiotherapy and the combined
treatment with X-rays and cytotoxic drug),
• alleviation of physical and psychic effects
of the disease and the treatment.
Among remedies applied in the treatment
of complications in the oral cavity caused
by irradiation, the following may be distin-
guished: drugs increasing saliva secretion
(pilocarpine hydrochloride, bromohexidine,
anethole-trithione, betanechol, guaifensine,
neostygmine, potassium iodide, nicotine
acid, apple acid, vitamin A, pills with xylitol,
sorbitol, and saliva substitutes), anti-
bacterial drugs (listerine, chlorohexidine,
triclosan, chlorchinaldin, nystatine), anti-
inflammatory drugs (salicylates, non-steroid
anti-inflammatory remedies, sucralaphate),
and alleviating drugs (Ems salt, camomile
infusion, salt solution, aminothiol).
The oldest and the most popular
medication applied to increase saliva
secretion is pilocarpine (Pilokarpinum
hydrochloricum), used in the 19th century
(Backman applied it for the first time in pa-
tients with xerostomy), leading to an incre-
ase in saliva and sweat secretion by sti-
mulating cholinergic muscarine receptors
(particularly in parasympathic neuration
of the outer secretion glands) [14,25,26,27].
The increase in the saliva secretion
by the salivary glands appears 30-45
minutes after the application and is pilo-
carpine to maintained for about 2-3 hours.
Overdosage may result in a decrease
in the blood pressure, bradicardis,
and bronchi cramp; if not treated, this may
lead to death due to lungs swell and/or
paralysis of the respiratory center. Usually,
the dose is 2.5-5 mg taken once or twice
daily [25,26,28].
Another medication worth noting in this,
group of drugs bromohexine (Bisolvan,
Bromhexin, Flegamina), used mainly in an
obtrusive lung disease. By depolymerizing
the slime mucoproteins, it causes lique-
faction of the discharge and makes removal
easier [26]. The application of bromo-
hexidine may cause a dicrease in IgA, IgM,
which may have an impact on the caries.
The average dose of bromohexidine is 4 mg
three times daily [26]. Another drug of this
group is anethole-thrithione (Sialor, Sul-
farlem S 25 Anetholetridone). The me-
chanism leading to an increase in saliva
secretion (74% of patients show an incre-
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ase in saliva secretion after 2 weeks)
is unknown. The usual dose is 25 mg three
times daily. Sometimes however, anethole-
thrithione may cause stomach and intestine
disorders [26]. The effects of betanechol
are similar to those of policarpine (stimu-
lation of cholinergic muscarine receptors).
The dose is 5 mg three times daily [26].
Additionally, cold tea with lemon, flax-seed
infusion or chewing gum are recommended
to stimulate saliva secretion [3,15]. Apart
from mechanical effects, chewing gum may
contain components increasing saliva
secretion, e.g. Biotene - dry mouth gum.
Sometimes saliva substitutes may bring
relief, e.g. Glandosane by Fresenius
or Artisial by Holphar. These substances
are applied if necessary several times daily
through sprinkling the mucous membrane
of the oral cavity and throat [29].
Among anti-bacterial drugs, Listerin,
Chlorhexidine, Triclosan and Chlorchinaldin
are recommended. Listerin consists of thy-
mol, menthol, eucalyptus extract in 20%
ethanol solution. It is characterized
by strong anti-bacterial, anti-viral (herpes
simplex, HIV), and anti-mycosal (Candida
albicans) action [28,30,31].
Chlorhexidine is a wide-range anti-
bacterial and bacteriostatic drug (mainly
Gram-positive bacteria). Being anti-bacterial
and anti-inflammatory it may be applied
as pills or a 0.05-0.1 % gargling solution
(4-5 times a day) [3,32]. Triclosan (Sicorten,
Irgasan DP 300), diluted at 0.8-6.3 micro-
gram/ml. The application of Chlorchinaldin
(anti-bacterial both for Gram-positive
and Gram-negative bacteria and anti-
mycosal remedy) is also recommended.
The dose is to 2 mg 4-7 times daily [3].
Ionizing radiation significantly affects
the composition of the oral cavity microflora.
A characteristic symptom of a possible
disorder is an increase in the mycosal flora,
particularly of the Candida type [16]. Thus,
it is necessary to apply an anti-mycosal
drug, such as Nystatine (anti-mycosal
and mycostatic). Nystatine is used as
an aqueous solution in the concentration
of 100,000 j. in 1 g, fluconazole (Diflucan) -
0.05 g daily for 7-14 days, miconazol
(Daktarin) - oral gel - 10ml (250 g) every
six hours, or Amphotericine B - suspension
- 1 ml (100 mg) every six hours
for 2-3 weeks (Heimdahl 1999). These
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drugs should be applied prior to radio-
therapy.
The anti-inflammatory medication
is applied include salicylates, benzdamine
(non-steroid anti-inflammory drugs),
sucralafat Ancrusal, Sucralfat ratio
(protects and regenerates the mucous
membrane) [33]. Additionally, Ems salt,
camomile infusion, and a salt solution are
used to prevent inflammation; they contract
and alleviate the mucous membrane [3,33].
When the treatment of patients with head
and neck tumours is started, the co-
operation between the patient and the tre-
atment team is important. Prior to the oc-
curence of undesirable side effects
of radiotherapy in the oral cavity the dentist
should initiate professional preventive
action and encourage the patient to pay
attention to the possibility complications
The hygiene of the oral cavity, performed
by the patient according the dentist's
instruction, plays an extremely important
role. It should be emphasized that despite
the discomfort connected with the basic
treatment, the patient should remember
of his or her oral cavity sanitation,
and of a regular screening of the mucous
membrane and teeth condition. The patient
himself or herself is not able to prevent side
effects of radiotherapy. Frequent screening
and professional intervention, leading
to alleviation of adverse symptoms
and reduction of suffering, offer a possibility
of a greater comfort by limiting the painful
effects of the therapy applied.
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